Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a cutting-edge biotech startup that developed a topical drug delivery system called NeuroDirect, a system that can be used to deliver psychedelic drugs directly to the brain, avoiding the traditional “high” and side effects.
The company is currently conducting trials in Australia for the treatment of PTSD and complex regional pain syndrome. Earlier this month, Psycheceutical announced the completion of dosing the first cohort of subjects in a Phase I clinical trial of its topical ketamine formulation for PTSD.
So Far, So Good
If successful, NeuroDirect could have applications for a wide range of neuro-related conditions, including Parkinson’s, drug addiction and traumatic brain injury.
Zappolin, who spoke at the April Benzinga Psychedelics Capital Conference in Miami explained that the company has also received a number of patents for topical back-of-the-neck drug delivery. This approach could …